Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia in a Newborn Treated With Remdesivir and Coronavirus Disease 2019 Convalescent Plasma

Hopwood, Andrew J.; Jordán-Villegas, Alejandro; Gutierrez, Liliana D; Cowart, Mallory C; Vega-Montalvo, Wilfredo; Cheung, Wang L.; McMahan, Michael; Gomez, Michael R.; Laham, Federico R.

doi:10.1093/jpids/piaa165

Cited by 21 publications

(15 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, only a limited number of case reports and case series have been published on the use of COVID-19 convalescent plasma in children (18)(19)(20)(21)(22)(23)(24)(25)(26) and a detailed pharmacokinetic analysis is lacking. In this prospective study, high-titer convalescent plasma appears to be safe when given to high-risk children.…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetics of high-titer anti–SARS-CoV-2 human convalescent plasma in high-risk children

Gordon¹,

Brosnan²,

Yoon³

et al. 2022

JCI Insight

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Pharmacokinetics of high-titer anti–SARS-CoV-2 human convalescent plasma in high-risk children

Gordon¹,

Brosnan²,

Yoon³

et al. 2022

JCI Insight

View full text Add to dashboard Cite

show abstract

“…12 Except the report by Goldman et al, 25 there are only a few case reports of children with COVID-19 treated with remdesivir. 26 27 28 29 Remdesivir became available for use in July 2020 in Korea. To our knowledge, no pediatric case of severe COVID-19 treated with remdesivir has been reported in Korea.…”

Section: Discussionmentioning

confidence: 99%

A Case Report for Severe COVID-19 in a 9-Year-Old Child Treated with Remdesivir and Dexamethasone

Hwang

Choi

2021

J Korean Med Sci

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is generally milder in children than in adults, and a substantial proportion of children with the disease have asymptomatic infections. Remdesivir is recommended for severe COVID-19. To date, there are little data on the outcomes of remdesivir treatment in children. We report a case of severe COVID-19 in a previously healthy but obese (body mass index, 27.6; 99.8 th percentile of the age) 9-year-old boy treated with remdesivir and dexamethasone. The patient had pneumonia at the time of diagnosis and required supplemental oxygen due to hypoxia one day after diagnosis. The patient developed respiratory distress as his pneumonia progressed rapidly. Therefore, remdesivir with dexamethasone therapy was initiated on hospital day 2. Supplemental oxygen was gradually weaned on hospital day 6 and stopped on hospital day 9. Significant improvement in pneumonic consolidations on chest X-ray was noted on hospital day 8. The patient was discharged on hospital day 21. We did not observe any adverse effects of remdesivir therapy and successfully treated a 9-year-old child with severe COVID-19.

show abstract

“…Citations of newborn infection have emerged on the basis of positive findings of viral RNA [21,32,34,40,52,76,94,95,127,136,152,218,227,245,[256][257][258][259][260]. As for maternal infections, viral RNA may be detected for a considerable period of time after infection onset [260].…”

Section: Neonatal Infectionsmentioning

confidence: 99%

“…It was not clear whether respiratory distress was solely attributable to COVID-19 in the latter report given the degree of prematurity. Hopwood et al found a term newborn to be seemingly infected in the first 25 h of life and decompensation included severe respiratory failure [257]. The mother may have had ruptured membranes for several days prior to vaginal delivery.…”

Section: Neonatal Infectionsmentioning

confidence: 99%

A Comprehensive Analysis of Maternal and Newborn Disease and Related Control for COVID-19

Cimolai

2021

SN Compr. Clin. Med.

View full text Add to dashboard Cite

The maternal-fetal/newborn unit is established at risk for COVID-19 infection. This narrative review summarizes the contemporary and cumulative publications which detail maternal infection, antenatal and newborn infections, and maternal/fetal/newborn management and prevention. There is a wide spectrum of maternal disease, but the potential for severe disease albeit in a minority is confirmed. COVID-19 carries risk for preterm delivery. Pregnant females can suffer multisystem disease, and co-morbidities play a significant role in risk. Congenital infection has been supported by several anecdotal reports, but strong confirmatory data are few. No typical congenital dysmorphisms are evident. Nevertheless, placental vascular compromise must be considered a risk for the fetus during advanced maternal infections. Clinical manifestations of newborn infection have been mild to moderate and relatively uncommon. Proven antiviral therapy is of yet lacking. The mode of delivery is a medical decision that must include patient risk assessment and patient directives. Both presymptomatic and asymptomatic mothers and offspring can complicate infection control management with the potential for spread to others in several regards. In the interim, infections of the maternal-fetal-newborn unit must be taken seriously both for the disease so caused and the potential for further dissemination of disease.

show abstract

Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia in a Newborn Treated With Remdesivir and Coronavirus Disease 2019 Convalescent Plasma

Cited by 21 publications

References 9 publications

Pharmacokinetics of high-titer anti–SARS-CoV-2 human convalescent plasma in high-risk children

Pharmacokinetics of high-titer anti–SARS-CoV-2 human convalescent plasma in high-risk children

A Case Report for Severe COVID-19 in a 9-Year-Old Child Treated with Remdesivir and Dexamethasone

A Comprehensive Analysis of Maternal and Newborn Disease and Related Control for COVID-19

Contact Info

Product

Resources

About